These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2232199)

  • 21. Selective depletion of CD8 positive T-lymphocytes for prevention of graft-versus-host disease following allogeneic bone marrow transplantation.
    Champlin R; Gajewski J; Feig S; Giorgi J; Lyddane N; Lee K; Schmidt I; Winston D; Ho W; Reichert T
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2947-8. PubMed ID: 2495694
    [No Abstract]   [Full Text] [Related]  

  • 22. Achieving alloengraftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation.
    Sykes M; Sharabi Y; Sachs DH
    Bone Marrow Transplant; 1988 Sep; 3(5):379-86. PubMed ID: 3056545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Graft failure and graft-vs-host disease after subtotal T-cell-depleted marrow transplantation: correlations with marrow hematopoietic and lymphoid subsets.
    Przepiorka D; Huh YO; Khouri I; Reading C; Hester J; Marshall M; Champlin RE
    Prog Clin Biol Res; 1994; 389():557-63. PubMed ID: 7700921
    [No Abstract]   [Full Text] [Related]  

  • 24. [Prevention of graft-vs-host disease following allogeneic bone marrow transplantation].
    de Witte T; Janssen J; de Pauw B; Holdrinet R; Wessels J; Haanen C
    Ned Tijdschr Geneeskd; 1986 Jul; 130(28):1290-1. PubMed ID: 3528870
    [No Abstract]   [Full Text] [Related]  

  • 25. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
    Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
    Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
    Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
    Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The immunological aspects of bone marrow transplantation].
    Okulov VB; Afanas'ev BV
    Vopr Onkol; 1992; 38(4):387-96. PubMed ID: 1300731
    [No Abstract]   [Full Text] [Related]  

  • 31. [Cellular sorting methods in autologous (elimination of residual malignant cells) or allogeneic (T lymphocyte elimination) bone marrow grafts. Clinical pilot studies].
    Hervé P; Flesch M
    Nouv Rev Fr Hematol (1978); 1986; 28(2):97-105. PubMed ID: 2942838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
    Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
    Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
    Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
    Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reconstitution of T cell subset repertoire diversity following multiple antigen-mismatched bone marrow transplantation.
    Friedman TM; Azhipa O; Zilberberg J; Tkachuk Y; Hsu JW; Rowley SD; Goldberg SL; Korngold R; Pecora AL; Preti RA
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1092-5. PubMed ID: 17084373
    [No Abstract]   [Full Text] [Related]  

  • 36. Preliminary characterization of functional residual host-type T lymphocytes following conditioning for allogeneic HLA-matched bone marrow transplantation (BMT).
    Kedar E; Or R; Naparstek E; Zeira E; Slavin S
    Bone Marrow Transplant; 1988 Mar; 3(2):129-40. PubMed ID: 3048477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [HLA-mismatched bone marrow transplantation].
    Hiraoka A; Masaoka T
    Nihon Rinsho; 1990 Sep; 48(9):1994-2002. PubMed ID: 2232202
    [No Abstract]   [Full Text] [Related]  

  • 38. Improved immune function with donor B-cell infusion after semi-allogeneic bone marrow transplantation in mice.
    Samuel S; Azar Y; Corchia N; Or R
    Arch Med Res; 2008 Jan; 39(1):61-8. PubMed ID: 18067997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Graft-versus-host disease in children receiving HLA-identical allogeneic bone marrow transplants with a low adjusted T lymphocyte dose.
    Potter MN; Pamphilon DH; Cornish JM; Oakhill A
    Bone Marrow Transplant; 1991 Nov; 8(5):357-61. PubMed ID: 1768970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T cell depletion from human bone marrow using magnetic beads.
    Knobloch C; Spadinger U; Rueber E; Friedrich W
    Bone Marrow Transplant; 1990 Jul; 6(1):21-4. PubMed ID: 2390629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.